PTJ
BBIO icon

Paul Tudor Jones’s BridgeBio Pharma BBIO Stock Holding History

Paul Tudor Jones’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,600
Closed -$964K – 3611
2025
Q4 		$964K Buy
+12,600
New +$827K ﹤0.01% 2299
2025
Q3 		– Sell
-14,500
Closed -$626K – 3356
2025
Q2 		$626K Buy
14,500
+100
+0.7% +$3.64K ﹤0.01% 2441
2025
Q1 		$498K Buy
+14,400
New +$486K ﹤0.01% 2288

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Paul Tudor Jones's BBIO Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 77,170 shares worth $5.75M. The stake represents 0.01% of the portfolio and ranks #1182 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in BBIO as recently as Q2 2025.

Paul Tudor Jones first reported a position in BBIO in Q2 2021 and has held it in 11 quarters since. 471 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Paul Tudor Jones held 77,170 shares of BridgeBio Pharma worth $5.75M as of Q2 2026.
  • BridgeBio Pharma was a new Paul Tudor Jones position in Q2 2026.
  • BridgeBio Pharma made up 0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1182 holding.
  • Paul Tudor Jones first reported a position in BridgeBio Pharma in Q2 2021 and has held it in 11 quarters since.
  • 471 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.